Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Tempest Therapeutics
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
May 29, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 6, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 29, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026
Tempest Reports Year End 2025 Financial Results and Provides Business Update
March 30, 2026
1
2
Next Page
→